Biotoxtech Co., Ltd.

As of March 31, 2026, Biotoxtech Co., Ltd. carries a market capitalization of 47.37B, placing it among publicly traded companies globally. Its enterprise value stands at 74.99B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, Biotoxtech Co., Ltd. has 15.41M shares outstanding.

As of March 31, 2026, Biotoxtech Co., Ltd. trades at a trailing price-to-earnings ratio of 62.15. The price-to-sales ratio is 1.00, and the price-to-book ratio stands at 1.24.

These figures are as of March 31, 2026. The EV/Sales ratio of 1.57 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 74.99B versus a market cap of 47.37B, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, Biotoxtech Co., Ltd. maintains a current ratio of 0.53, meaning it holds 0.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 212.65, indicating elevated leverage, while an interest coverage ratio of -0.15 demonstrates limited ability to service its debt obligations.

Over the twelve months ended March 31, 2026, Biotoxtech Co., Ltd. posted a return on equity (ROE) of 2.00, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 0.58, measuring how efficiently the asset base is converted into earnings. The company generates approximately 202.28M in revenue per employee across its workforce of 235.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 4.07 indicates how many times Biotoxtech Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, Biotoxtech Co., Ltd. recorded 1.34B in income tax expense. The company reported a pretax loss of -887.30M and 769.13M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, Biotoxtech Co., Ltd.'s stock has declined approximately 26.26% over the past 52 weeks. The 50-day moving average sits at 2,280.70, while the 200-day moving average is 2,642.33.

Over the twelve months ended March 31, 2026, Biotoxtech Co., Ltd. generated 47.64B in revenue and converted that into 769.13M in net income, yielding earnings per share of -137.92. EBITDA reached -825.11M, while operating income came in at -5.21B.

As of March 31, 2026, Biotoxtech Co., Ltd. holds 25.52B in cash and equivalents against 62.19B in total debt, resulting in a net debt position of 46.37B. Total book value stands at 38.30B, with working capital of -41.32B providing operational flexibility.

Biotoxtech Co., Ltd. produced 6.64B in operating cash flow over the twelve months ended March 31, 2026. After subtracting -3.15B in capital expenditures, free cash flow totaled 3.49B - equivalent to 224.45 per share.

Over the twelve months ended March 31, 2026, Biotoxtech Co., Ltd. posted a gross margin of 11.86, reflecting its pricing power and cost economics. The operating margin of -10.94 and net profit margin of 1.61 provide insight into operational efficiency.

These figures cover the twelve months ended March 31, 2026. Free cash flow yield stands at 7.03, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 14.44, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Biotoxtech Co., Ltd. shareholders.

Biotoxtech Co., Ltd.'s most recent stock split took place on September 25, 2014.

As of March 31, 2026, Biotoxtech Co., Ltd. has an Altman Z-Score of 0.13, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.